Scarica l'app Stockscreener
15.29
1.74%
-0.27
Dopo l'orario di chiusura:
15.55
0.26
+1.70%
Precedente Chiudi:
$15.56
Aprire:
$15.41
Volume 24 ore:
519.99K
Relative Volume:
0.80
Capitalizzazione di mercato:
$1.42B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-3.8611
EPS:
-3.96
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
-6.83%
1M Prestazione:
-8.17%
6M Prestazione:
-2.61%
1 anno Prestazione:
-6.60%
Intervallo 1D:
$15.03
$15.50
Intervallo di 1 settimana:
$15.00
$16.71
Portata 52W:
$12.95
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus says Gilead-partnered cancer therapy cut death risk by 36% - Seeking Alpha
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer - StockTitan
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings - GuruFocus.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
(RCUS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
This Arcus Biosciences Insider Reduced Their Stake By 27% - Simply Wall St
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for - MSN
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting - StockTitan
Arcus Biosciences (RCUS) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Arcus Biosciences: Advancing On Several Fronts (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Trading Down 5.3%Should You Sell? - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $29.00 at Barclays - MarketBeat
Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials - Investing.com India
Arcus Begins Differentiating Its HIF-2a inhibitor Versus Merck’s Welireg - Scrip
Arcus Biosciences Announces New Employment Inducement Grants - StockTitan
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - Marketscreener.com
Citi raises Arcus Biosciences target to $46, maintains buy By Investing.com - Investing.com Canada
Arcus Biosciences (RCUS) PT Raised to $46 at Citi - StreetInsider.com
Neutral stance on Arcus Biosciences maintained by BofA - Investing.com Canada
BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS) - StreetInsider.com
Arcus Biosciences (NYSE:RCUS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (NYSE: RCUS) Could Slash -153.89% Soon - Stocks Register
Arcus Biosciences Shares Rise After Kidney Cancer Drug Shows Promise in Early-Stage Trial - MarketWatch
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer - StockTitan
(RCUS) Technical Pivots with Risk Controls - Stock Traders Daily
Arcus Begins Differentiating Its HIF-2a Inhibitor Versus Merck’s Welireg - Citeline
Arcus started at neutral by H.C. Wainwright, upcoming data cited - MSN
Research Analysts Issue Forecasts for RCUS Q3 Earnings - MarketBeat
Exchange Traded Concepts LLC Has $152,000 Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
HC Wainwright Initiates Coverage on Arcus Biosciences (NYSE:RCUS) - Defense World
PD-1 Non-Small Cell Lung Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Summit Therapeutics, Arcus Biosciences,GSK, Pfizer - The Globe and Mail
HC Wainwright & Co. Initiates Coverage of Arcus Biosciences (RCUS) with Neutral Recommendation - MSN
Arcus started at neutral by H.C. Wainwright, upcoming data cited (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Shares Gap DownTime to Sell? - MarketBeat
Neutral rating set for Arcus Biosciences shares ahead of data release - Investing.com UK
Unveiling 5 Analyst Insights On Arcus Biosciences - Benzinga
Where Arcus Biosciences Stands With Analysts - Benzinga
Arcus Biosciences (NYSE:RCUS) Receives New Coverage from Analysts at HC Wainwright - MarketBeat
State Street Corp's Strategic Adjustment in Arcus Biosciences Ho - GuruFocus.com
December 20th Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
SG Americas Securities LLC Decreases Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Inc (RCUS)’s results reveal risk - US Post News
PD-1 and PDL-1 Inhibitors Market -2032 Demanding Key Players like GlaxoSmithKline plc, Bristol-Myers Squibb Company, Arcus Biosciences, Inc. – Cauverynews - Cauverynews
Objective long/short (RCUS) Report - Stock Traders Daily
Squarepoint Ops LLC Purchases New Shares in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Buy” from Analysts - Defense World
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) PT at $34.88 - MarketBeat
Commit To Buy Arcus Biosciences At $15, Earn 30.4% Annualized Using Options - Nasdaq
The RCUS Stock Puzzle: Unraveling Arcus Biosciences Inc’s Fluctuating Performance - The InvestChronicle
Arcus Biosciences (NYSE:RCUS) Shares Down 5.1%Should You Sell? - MarketBeat
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):